KPV Capsules and Cream: Oral and Topical KPV Under the HHS Peptide Policy

Since October 28, 2026, HHS has said it will not take enforcement action against a state-licensed pharmacy that compounds KPV for a named patient, but only as KPV acetate and only in oral or topical forms.^[1] Injections and nasal sprays are outside the policy, and so are blends such as “Klow.” Capsules carry one more hurdle: the pharmacy is expected to hold documentation that its formulation is absorbed well enough in people.^[1] No such human data has been published. Everything known about swallowing KPV or putting it on skin comes from mice, rats and lab tissue, and no human study has measured its side effects.^[2]

What the HHS policy covers for KPV

The policy lists six peptides and attaches a route limit to each. For KPV, Appendix B says enforcement discretion “is appropriate for topical and oral dosage forms” of KPV acetate made from an ingredient with a certificate of analysis that meets the policy’s conditions.^[1] It is interim. It lasts until FDA decides by final rule whether KPV goes on the 503A bulks list, and HHS says it may revisit the policy if a safety signal or quality problem appears.^[1] It does not approve KPV: in the policy’s own words, compounded drugs “are not FDA-approved.”^[1] The full HHS policy explainer covers the other five peptides and all ten conditions.

HHS gave three reasons for including KPV at all. Use is now documented, mostly as single-ingredient products. Lots supplied to pharmacies now confirm KPV’s identity by mass spectrometry and report the endotoxin and microbial results that FDA’s drug center had found missing. And, in HHS’s reading, the drug center’s safety conclusion “reflects an absence of information rather than an observed signal.”^[1] The drug center itself had recommended against listing KPV in either form.^[1]

Condition 8: the rule for KPV capsules

Of the six peptides, only BPC-157 and KPV are covered in a form you swallow. For both, the policy adds a requirement aimed squarely at capsules:^[1]

“Achieving adequate oral bioavailability of peptides is inherently difficult and complex. Therefore, if a peptide is compounded in an oral dosage form, the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.”^[1]

— HHS Enforcement Discretion Policy, condition 8

Three phrases in that sentence carry weight. “Specific formulation” means the pharmacy’s own capsule, with its own fillers and coating, and not KPV in general. “In humans” rules out leaning on mouse data. And the policy never defines “adequate”, so it sets no level that counts.

When FDA reviewed KPV for its July 2026 advisory committee, it found no pharmacokinetic studies of KPV in people by any route, meaning no measurement of how much reaches the blood or the gut wall after a dose.^[2] A pharmacy offering KPV capsules under the policy would therefore need data that has not appeared in the published literature. That does not mean no pharmacy has it. It does mean the question is fair to ask, and a pharmacy operating under the policy should be able to answer it. The same rule applies to oral BPC-157 capsules.

There is a wrinkle specific to KPV. Most of its animal research aims at the lining of the colon, where the peptide is meant to act locally. Bioavailability usually means how much of a dose reaches the bloodstream, and a drug meant to work inside the gut may not need much of that. The policy does not say which measure it expects for a peptide like KPV.

What the animal studies show about swallowing KPV

KPV has one advantage most peptides lack: it is small enough to ride a transporter. PepT1 carries two- and three-amino-acid peptides from digested food into cells. It is normally found in the small intestine and is switched on in the colon during inflammatory bowel disease. A 2008 study from Emory University showed that KPV enters gut and immune cells through PepT1, and that mice given KPV in their drinking water had less chemically induced colitis.^[3]

Plain KPV still has to survive the trip. In lab stress tests, it breaks down in acid, alkali and peroxide, mainly into a ring-shaped fragment called lys-pro-diketopiperazine.^[10][2] A rat study described KPV in solution as “very unstable” when given rectally.^[8] That is why most of the oral work since 2010 has gone into packaging:

The Cheng study is the most telling for capsule buyers. Its authors start from the premise that oral peptides suffer from “degradation and poor intestinal absorption,” and their engineered version delivered nearly four times as much KPV to the colon as the plain peptide.^[6] Two of the authors are inventors on a pending patent related to the work.^[6] The comparison suggests that much of a plain oral dose never reaches the target, at least in mice. A compounded capsule is a far simpler product than any of these systems, and none of them has been tested in a person.

KPV on the skin

Topical KPV is the form that started the regulatory process. The compounding pharmacy that nominated KPV to FDA proposed a 0.1% cream or gel; the nomination was later withdrawn, and FDA kept reviewing KPV on its own initiative.^[2] The main obstacle is getting through the outer layer of skin. In donated human skin in a lab chamber, KPV applied on its own did not pass through at detectable levels. Pricking the skin with microneedles raised the rate to 4.4 micrograms per square centimeter per hour, and adding a small electric current raised it further.^[9]

FDA drew two conclusions from that study. Poor penetration could limit how much KPV from a cream reaches the bloodstream, which would reduce the risk of whole-body effects. It could also keep KPV from reaching the deeper skin layers where it would need to act.^[2] A cream sold as anti-inflammatory therefore has an open question built in, and no human study has answered it.

The rest of the topical evidence is in cells and animals. A 2025 Korean study found that KPV reduced inflammation and cell death in human skin cells and a lab-grown skin model exposed to fine dust; its first author works for a company, and the paper points to cosmetic uses.^[11] A 2021 study put KPV in a gel that sticks to the gums of rats with chemotherapy mouth sores, and treated rats ate and regained weight better.^[12] FDA noted that researchers have called for clinical studies on skin wounds and ulcers; none had been done.^[2]

KPV side effects: what is known

No KPV side effects have been documented in people, because KPV has never been studied in people. FDA found no clinical studies or human exposure data by any route and concluded that “potential safety risks associated with the use of KPV in humans are unknown.”^[2] It also found no acute toxicity studies in animals.^[2]

• Adverse event reports. FDA’s database held none for KPV through December 3, 2025. FDA adds that 503A compounders generally do not report adverse events to it, so the empty record says little.^[2]
• Immune reactions. Peptides can provoke antibodies and can clump together, which raises that risk. FDA found no data on either for KPV.^[2]
• Topical products. Poor skin penetration may keep blood levels low, but whether broken or treated skin lets more through has not been tested in living people.^[2]
• Breakdown products. Degraded KPV forms lys-pro-diketopiperazine, so storage and stability matter for any cream or capsule.^[10]

The policy is built to start filling that gap. Condition 5 requires compounders to report serious adverse events to FDA’s MedWatch program whether or not they seem drug-related, and to print the reporting procedure on the patient’s labeling.^[1] If you use compounded KPV and have a reaction, tell your prescriber and report it.

KPV dosage, and morning or night

No dose of KPV is approved or has been tested in a human study. The doses in the animal papers were set for mice and rats and for delivery systems unlike a compounded capsule or cream, so they do not translate to people. No study has compared taking KPV in the morning with taking it at night. Any timing or dosage chart online is a guess. Under the policy, a compounded product still needs a prescriber, and the strength and directions come from that prescription.^[1]

Why injectable KPV and Klow blends sit outside the policy

FDA found KPV promoted online as single-ingredient injections, oral products, topical products and nasal sprays, and in multi-ingredient products with BPC-157, TB-500, AOD-9604 and follistatin-344.^[2] Under the policy, two of those formats fail on route and the blends fail on ingredient count. Condition 2 ties each peptide to the routes in Appendix B, and for KPV that excludes injection and nasal use. Condition 7 limits each product to a single active ingredient, so that adverse events can be traced to one substance.^[1]

“Klow” is the name sellers commonly use for an injectable blend of GHK-Cu, BPC-157, TB-500 and KPV. It breaks the policy three ways: it is a blend, it is injected, and GHK-Cu is not one of the six listed peptides. Our blends and stacks review covers Glow, Klow and the BPC-157 and TB-500 pair in detail. A KPV vial labeled “research use only” is outside the policy for a different reason: no pharmacy, no prescription and no certificate tied to a registered manufacturer. Our guide to research-use-only versus compounded peptides explains the difference.

Questions to ask before using KPV capsules or cream

1. Is it single-ingredient KPV acetate? The policy names the acetate form, by one active ingredient only.^[1]
2. For capsules: where is the human bioavailability documentation? Condition 8 expects the pharmacy to hold it for the specific formulation you receive.^[1]
3. Which FDA-registered facility made the ingredient? The certificate of analysis should name it and report identity, purity, potency, endotoxin and microbial results. Our guide to reading a peptide certificate of analysis shows what to look for.
4. Does the label read “This is a compounded drug product. Not for resale.”? Condition 6 requires that wording, and the labeling should explain how to report problems.^[1]
5. Is it a 503A pharmacy filling a prescription in your name? The policy covers nothing else. Our explainer on 503A and 503B pharmacies covers the difference.

For the sellers, our KPV profile covers where it is offered, and the KPV provider comparison ranks the telehealth sellers that list it.